MicroRNAs (miRNAs) are widely expressed in organisms and are implicated in the regulation of most biological functions. The present study investigated the association of plasma miRNAs with the clinical outcomes of dual antiplatelet therapy in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Plasma miRNA levels were screened using high-throughput Illumina sequencing to evaluate the antiplatelet efficacy of clopidogrel and aspirin. Six plasma miRNAs (miR-126, miR-130a, miR-27a, miR-106a, miR-21, and miR-142) were associated with clopidogrel-treated platelet aggregation. These miRNAs were validated in a prospective cohort of 1230 CAD patients using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). High plasma miR-142 levels were associated with a high risk of major adverse cardiovascular events (MACE), with a hazard ratio (95% confidence interval) of 1.83 (1.30-2.59) at a false discovery rate of <5%. Multivariable Cox regression analysis revealed that diabetes mellitus, heart failure, calcium channel blocker application, and a high plasma miR-142 level were independent risk factors of MACE. The levels of the six plasma miRNAs were not significantly associated with bleeding events during the 3-year follow-up. In conclusion, plasma miR-142 is potential marker to predict MACE in CAD patients after PCI.

中文翻译：

---

血浆miR-142预测重大心血管不良事件是双重抗血小板治疗的中间生物标志物。

微小RNA（miRNA）在生物体中广泛表达，并参与大多数生物学功能的调节。本研究调查了血浆miRNA与经皮冠状动脉介入治疗（PCI）的冠状动脉疾病（CAD）患者双重抗血小板治疗的临床结局。使用高通量Illumina测序筛选血浆miRNA水平，以评估氯吡格雷和阿司匹林的抗血小板功效。六个血浆miRNA（miR-126，miR-130a，miR-27a，miR-106a，miR-21和miR-142）与氯吡格雷治疗的血小板聚集有关。使用定量逆转录-聚合酶链反应（qRT-PCR）在1230名CAD患者的预期队列中验证了这些miRNA。血浆miR-142高水平与重大不良心血管事件（MACE）的高风险相关，危险比（95％置信区间）为1.83（1.30-2.59），错误发现率低于5％。多变量Cox回归分析显示，糖尿病，心力衰竭，钙通道阻滞剂的应用和血浆miR-142的高水平是MACE的独立危险因素。在三年的随访中，六个血浆miRNA的水平与出血事件没有显着相关。总之，血浆miR-142是预测PCI后CAD患者MACE的潜在标志物。钙通道阻滞剂的应用和血浆miR-142的高水平是MACE的独立危险因素。在三年的随访中，六个血浆miRNA的水平与出血事件没有显着相关。总之，血浆miR-142是预测PCI后CAD患者MACE的潜在标志物。钙通道阻滞剂的应用和血浆miR-142的高水平是MACE的独立危险因素。在三年的随访中，六个血浆miRNA的水平与出血事件没有显着相关。总之，血浆miR-142是预测PCI后CAD患者MACE的潜在标志物。